글로벌 폐 약물 전달 시장 – 2030년까지의 산업 동향 및 예측

폐 약물 전달 시장 분석 및 규모

폐 약물 전달로 알려진 약물 전달 경로의 주요 목표는 흡입된 약리학적 제제를 입을 통해 약물 제형을 흡입하는 데 도움이 되는 장치로 하부 기도에 넣는 것입니다. 이는 병원, 진료소 및 가정 간병 환경을 포함한 다양한 최종 사용자 산업에서 광범위하게 사용됩니다. 네뷸라이저, 정량 흡입기 및 건조 분말 흡입기를 포함하여 수많은 장치가 호흡 전달에 사용됩니다. 흡입 베타 작용제, 코르티코스테로이드 및 항콜린제 약물은 천식 및 만성 폐쇄성 폐 질환(COPD)을 치료하기 위해 폐를 통해 전달됩니다. 폐 투여 경로에는 여러 가지 장점이 있습니다. 약물은 호흡기 질환을 치료하기 위해 질병 부위에 직접 투여됩니다.

Data Bridge Market Research는 2022년에 478억 5천만 달러 규모였던 폐 약물 전달 시장이 2030년까지 728억 8천만 달러 규모로 성장하여 2023년에서 2030년까지의 예측 기간 동안 5.4%의 CAGR로 성장할 것으로 분석했습니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

폐 약물 전달 시장 범위 및 세분화  

시장 정의

약물을 의도한 부위로 보내는 것을 "표적 약물 전달"이라고 합니다. 폐 약물 전달이라고 하는 표적 약물 전달 시스템은 약물 부분을 하부 호흡 기관으로 향하게 해야 합니다. 폐 경로를 통해 신체에 약물을 투여하는 데 사용되는 장치를 폐 약물 전달 시스템이라고 합니다. 흡입 경로는 천식과 만성 폐쇄성 폐 질환을 치료하는 데 있어 경구 투여보다 우수한 대안을 제공합니다. 폐 약물 전달의 즉각적인 작용은 급성 기관지염과 천식 발작을 완화합니다. 폐 약물 전달의 경우 에어로졸은 특별히 제작된 장치입니다.

폐 약물 전달 시장 역학

운전자

• 심각한 호흡기 질환의 유병률 증가로 수요 급증

 낭포성 섬유증 및 만성 폐쇄성 폐질환과 같은 심각한 호흡기 질환의 유병률 증가는 폐 약물 전달 시장의 성장을 촉진하고 있습니다. 또한, 최소 침습적이고 효과적인 치료법에 대한 수요 증가와 넓은 다공성 영역, 얇은 흡수성 점막, 효율적인 혈액 공급의 특징으로 인한 폐 약물 전달의 증가 추세는 시장 성장을 촉진할 것입니다. 또한, 흡연 유병률 증가는 호흡기에 영향을 미쳐 시장의 전반적인 성장을 더욱 가속화할 수 있습니다.

•  폐질환의 유병률이 시장을 주도합니다

천식 및 만성 폐쇄성 폐질환과 같은 폐질환의 유병률에 대한 대기 오염의 증가는 병원과 진단 시설의 수를 늘리고, 폐질환 치료를 위한 민간 및 공공 기관의 자금 지원이 급증하고, 폐 건강에 대한 대중의 인식이 높아지는 것이 폐 약물 전달 시스템의 글로벌 시장을 주도하는 주요 요인입니다. 세계보건기구는 10명 중 9명이 오염 물질이 높은 공기를 호흡한다고 보고하고 있으며, 2018년에는 주변(실외) 및 가정의 대기 오염으로 인해 연간 700만 명이 사망할 것이라는 추산이 있습니다.

기회

• 기술 발전으로 인해 온라인 쇼핑이 시장을 활성화하고 있습니다.

Emerging markets and online channels are anticipated to expand and experience technological advancements to open up profitable market opportunities. The trend and demand for online shopping are growing due to its comfort, adaptability, and convenience, boosting the revenue generated by this market. Customers can also get discounts when they shop online. Additionally, the sum of these factors will increase demand for online pharmacies, and the advantages such as low cost and quick preparation and administration times, will persuade users to use these inhalers more frequently. Thus, with the technological advancements that have made dry powder inhalers a preferred medical device for treating various respiratory disorders, the use of these products has increased. Thus it will help in the expansion of the market.

• Hospital pharmacies are more trustable by people, which creates expansion in market

The segment of hospital pharmacies held the most significant percentage of the patient-determined disease steps and is anticipated to maintain that position going forward. Patients favor hospital pharmacies because they offer comprehensive medical care, quick reimbursements, and insurance policies. In addition, a rise in hospitalizations is anticipated to spur this market's expansion

Restraints/Challenges

• Lack of knowledge prevents the market from expansion

Drugs' expiring patents and general ignorance could obstruct the market's expansion. The general public's lack of knowledge about nasal drug delivery methods hinders market expansion. The technique for administering the doses must be explained to the patients. This limits the market's expansion for pulmonary drug delivery systems. The overall market revenue is hindered during the forecast period by inadequate training, a lack of understanding, and improper usage.

• High costs and strict regulations may limit the market

The market is growing due to numerous healthcare foundations and government initiatives for treating pulmonary diseases. However, the market is constrained by the high costs associated with pulmonary drug delivery system devices. The potential for implanted device failures and inadequate reimbursement in developed economies hampers the market's expansion. The growth of the overall market is also hampered by the strict regulatory policies for procedures and the high cost of treatment.

This pulmonary drug delivery market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pulmonary drug delivery market contact Data Bridge Market Research for an analyst brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2022, Subintro's acquisition by RIGImmune gave it access to cutting-edge topical delivery systems. With this agreement, the biotech is better positioned to advance the creation of cutting-edge RNA therapies and vaccine adjuvants for local mucosal delivery.
• In 2022, Orbital Dry Powder Inhaler (DPI) worldwide license was acquired by Aptar Pharma. This acquisition will enable Aptar Pharma to meet the rising demand for easy and secure high-dose lung treatment administration.
• In 2020, The U.S. Food and Drug Administration (FDA) received a New Drug Application (NDA) for UPTRAVI (selexipag) as an intravenous (IV) injection to treat pulmonary arterial hypertension from Johnson & Johnson's Janssen Pharmaceutical Companies.
• In 2020, The Japanese Ministry of Health, Labour, and Welfare (MHLW) simultaneously approved new treatment options for Japanese patients, according to news released by Novartis Pharma K.K. ("Novartis Pharma"). For advanced and recurrent untreatable non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation, TabrectaTM (capmatinib, formerly INC280) is an oral MET inhibitor.

Global Pulmonary Drug Delivery Market Scope

The pulmonary drug delivery market is segmented on the basis of formulations, canister type, application, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Formulations

• Type
• Suspension aerosol
• Solution Aerosal
• Dry power formulation
• Device type
• Dry Powder Inhalers
• Single-Dose Inhalers
• Multi-Dose Inhaler
• Metered Dose Inhalers
• Manually-Actuated Pressurized Inhaler
• Breath-Actuated Pressurized Inhaler
• Nebulizers
• Jet Nebulizers
• Soft Mist Nebulizers
• Ultra Wave Nebulizers
• Mesh
• Vibrating
• Static
• Pneumatic
• Vented
• Breath Actuated
• Accessories

Canister Type

• Plain Canister
• Coated Canister

Application

• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Cystic Fibrosis
• Allergic Rhinitis
• Other

End-User

• Hospitals and Clinics
• Home Care Settings

Pulmonary Drug Delivery Market Regional Analysis/Insights

The pulmonary drug delivery market is analysed and market size insights and trends are provided by country, formulations, canister type, application, and end-user as referenced above.

The countries covered in the pulmonary drug delivery market  report are  U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the growing prevalence of respiratory and lung disorders, technological advancement, and increasing awareness. Furthermore, through an increase in the prevalence of pulmonary diseases, the presence of major players in the production and development of drugs for pulmonary diseases, an increase in the number of hospitals and diagnostic facilities, and government initiatives for treating pulmonary diseases in the area.

Asia-Pacific is expected to show a rapid and lucrative growth rate in the forecast period owing to Japan's increasing disposable and rising geriatric population. Moreover, the rising patient count with respiratory and acceptance of pulmonary drug devices will boost the region market, whereas increasing government initiatives to improve healthcare infrastructure will also expand market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Pulmonary Drug Delivery Market Share Analysis

The pulmonary drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pulmonary drug delivery market.

Some of the major players operating in the pulmonary drug delivery market are:

• F. 호프만-라 로슈 유한회사(스위스)
• 맨카인드 코퍼레이션(미국)
• OMRON Healthcare, Inc. (일본)
• 마일런 NV(미국)
• 3M(미국)
• Koninklijke Philips NV(네덜란드)
• 머크앤코(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• Sunovion Pharmaceuticals Inc. (미국)
• PARI GmbH(독일)
• 주식회사 자빌(미국)
• 아스트라제네카(영국)
• 베링거 인겔하임 인터내셔널 GmbH. (독일)
• GSK plc. (영국)
• 노바티스 AG(스위스)
• Aerogen Pharma(아일랜드)
• 브릭스 헬스케어(미국)
• HAAG-STREIT GROUP(스위스)
• Janssen Global Services, LLC(미국)
• AptarGroup, Inc. (미국)

SKU-12286